Page last updated: 2024-10-23

bepridil and Breast Cancer

bepridil has been researched along with Breast Cancer in 2 studies

Bepridil: A long-acting calcium-blocking agent with significant anti-anginal activity. The drug produces significant coronary vasodilation and modest peripheral effects. It has antihypertensive and selective anti-arrhythmia activities and acts as a calmodulin antagonist.
bepridil : A tertiary amine in which the substituents on nitrogen are benzyl, phenyl and 3-(2-methylpropoxy)-2-(pyrrolidin-1-yl)propyl.

Research Excerpts

ExcerptRelevanceReference
"Triple-negative breast cancer (TNBC) is the most lethal form of breast cancer."1.43Pharmacological activation of FOXO3 suppresses triple-negative breast cancer in vitro and in vivo. ( Berek, JS; Chung, YM; Hu, MC; Ma, J; Park, SH; Yang, Q, 2016)

Research

Studies (2)

TimeframeStudies, this research(%)All Research%
pre-19900 (0.00)18.7374
1990's1 (50.00)18.2507
2000's0 (0.00)29.6817
2010's1 (50.00)24.3611
2020's0 (0.00)2.80

Authors

AuthorsStudies
Park, SH1
Chung, YM1
Ma, J1
Yang, Q1
Berek, JS1
Hu, MC1
Fu, LW1
Pan, QC1
Lin, GY1

Other Studies

2 other studies available for bepridil and Breast Cancer

ArticleYear
Pharmacological activation of FOXO3 suppresses triple-negative breast cancer in vitro and in vivo.
    Oncotarget, 2016, Jul-05, Volume: 7, Issue:27

    Topics: Animals; Apoptosis; Bepridil; Breast Neoplasms; Cell Nucleus; Dopamine; Female; Forkhead Box Protein

2016
[Compared study on Fura-2/AM assay and MTT assay for screening multidrug resistant modulators].
    Yao xue xue bao = Acta pharmaceutica Sinica, 1997, Volume: 32, Issue:6

    Topics: Bepridil; Breast Neoplasms; Calcium Channel Blockers; Drug Resistance, Multiple; Drug Resistance, Ne

1997